<DOC>
	<DOCNO>NCT00003812</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug give radiation therapy may effective treatment limited-stage small cell lung cancer . PURPOSE : Phase II trial study effectiveness chemotherapy plus radiation therapy treat patient limited-stage small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete response rate 2 course paclitaxel topotecan follow consolidation chemoradiotherapy patient limited stage small cell lung cancer . II . Determine toxic effect regimen patient population . III . Describe pattern relapse , document carefully location relapse respect original disease volume radiation treatment field patient . IV . Determine overall failure free survival patient . OUTLINE : Patients receive topotecan IV day 1-5 paclitaxel IV 3 hour day 1 . Filgrastim ( G-CSF ) administer subcutaneously every day start day 6 blood count recover . The course repeat begin day 22 . After restaging , patient begin thoracic radiotherapy daily , five day per week , 6-7 week . On day radiotherapy begin , patient receive carboplatin IV 1 hour ( day 43 ) etoposide IV 1 hour daily 3 day ( day 43-45 ) . The consolidation chemotherapy repeat every 21 day total 3 course . Patients stable respond disease undergo prophylactic cranial irradiation . Patients follow least every 3 month 2 year , every 6 month 3 year , least every year . PROJECTED ACCRUAL : A total 70 patient accrue study within 15-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm limited stage small cell lung cancer Includes disease restrict one hemithorax regional lymph node metastasis , include hilar , ipsilateral contralateral mediastinal lymph node Clinically suspect confirmed supraclavicular lymph node metastases pleural effusion visible plain chest radiograph , whether cytologically positive , eligible Unidimensionally bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2 time upper limit normal ( ULN ) Renal : Creatinine great ULN Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent active second malignancy except nonmelanoma skin cancer ( i.e. , complete therapy consider less 30 % risk relapse ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy small cell lung cancer No concurrent chemotherapy Endocrine therapy : No concurrent steroid except adrenal failure No concurrent hormone except nondisease relate condition ( e.g. , insulin diabetes ) No concurrent dexamethasone except intermittent use antiemetic adjunct prophylactic cranial irradiation Radiotherapy : No prior mediastinal radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>